Vertex Stock Loses Around $3B in 3 Months: Buy the Dip or Steer Clear? [Yahoo! Finance]
CRISPR Therapeutics AG - Common Shares (CRSP)
Last crispr therapeutics ag - common shares earnings: 8/7 05:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
nasdaq.com/symbol/crsp/real-time
Company Research
Source: Yahoo! Finance
the past three months, losing almost $3 billion of its market value. A key reason for the stock price dip was the loss recorded by the company in the second quarter due to costs related to the $4.9 billion acquisition of Alpine Immune Sciences, which closed in May. Vertex enjoys a dominant position in the cystic franchise (“CF”) market. Vertex's CF sales continue to grow, driven by its triple therapy, Trikafta/Kaftrio. Vertex has additional near-term launches planned — suzetrigine in acute pain and vanzacaftor triple combination (vanza triple) in CF. It is rapidly progressing its mid- and earlier-stage pipeline, with multiple milestones expected in the next 12 months. Let's understand the company's strengths and weaknesses to better analyze how to play the stock given the recent dip in price. Consistent Rise in VRTX's CF Product Sales Positive regulatory approvals have led to an increase in the eligible patient population for Vertex's approved medicines in the past 5-6 years.
Show less
Read more
Impact Snapshot
Event Time:
CRSP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRSP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRSP alerts
High impacting CRISPR Therapeutics AG - Common Shares news events
Weekly update
A roundup of the hottest topics
CRSP
News
- CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should Know [Yahoo! Finance]Yahoo! Finance
- Ark Next Generation Internet ETF vs. Ark Innovation ETF: Which Is Best for You? [Yahoo! Finance]Yahoo! Finance
- Crispr Therapeutics: Casgevy Now Active Across 35 Treatment Centres [Seeking Alpha]Seeking Alpha
- Gene Editing Therapeutics Market Forecast 2024-2029: A $1 Billion Market by 2029, with a Forecasted CAGR of 147% [Yahoo! Finance]Yahoo! Finance
- Why Is CRISPR Therapeutics (CRSP) Down 7.7% Since Last Earnings Report? [Yahoo! Finance]Yahoo! Finance
CRSP
Earnings
- 8/5/24 - Miss
CRSP
Sec Filings
- 8/12/24 - Form 4
- 8/5/24 - Form S-3ASR
- 8/5/24 - Form S-8
- CRSP's page on the SEC website